[en] Glioblastoma represents the most common primary malignancy of the central nervous system in adults and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wild-type setting may provide directions for future precision therapies. Here, we review recent learnings in the field, and further consider how tumour microenvironment differences across subtypes may reveal novel contexts of vulnerability. We discuss recent treatment approaches and ongoing trials in the IDH-wild-type glioblastoma setting, and propose an integrated discovery stratagem incorporating multi-omics, single-cell technologies and computational approaches.
Disciplines :
Oncology
Author, co-author :
White, K; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Connor, K; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Clerkin, J; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland, National Neurosurgical Department, Beaumont Hospital, Dublin, Ireland.
Murphy, B M; Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Salvucci, M; Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
O'Farrell, A C; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
REHM, Markus;
Universität Stuttgart, Germany
O'Brien, D; National Neurosurgical Department, Beaumont Hospital, Dublin, Ireland.
Prehn, J H M; Centre for Systems Medicine, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland.
NICLOU, Simone P. ; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg.
Lamfers, M L M; Department of Neurosurgery, Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Verreault, M; Sorbonne Université, Institut du Cerveau et de la Moelle Épinière, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie, Paris, France.
Idbaih, A; Sorbonne Université, Institut du Cerveau et de la Moelle Épinière, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie, Paris, France.
Verhaak, R; Jackson Laboratory for Genomic Medicine, Farmington, USA.
GOLEBIEWSKA, Anna ; NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg.
Byrne, A T; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: annettebyrne@rcsi.com.
Ostrom, Q.T., Gittleman, H., Truitt, G., et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:suppl_4 (2018), iv1–iv86.
Claes, A., Idema, A.J., Wesseling, P., Diffuse glioma growth: a guerilla war. Acta Neuropathol 114:5 (2007), 443–458.
Kleihues, P., Ohgaki, H., Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1:1 (2004), 44–51.
Ceccarelli, M., Barthel, F.P., Malta, T.M., et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:3 (2016), 550–563.
Nørøxe, D.S., Poulsen, H.S., Lassen, U., Hallmarks of glioblastoma: a systematic review. ESMO Open, 1(6), 2016, e000144.
Louis, D.N., Perry, A., Reifenberger, G., et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:6 (2016), 803–820.
Kristensen, B.W., Priesterbach-Ackley, L.P., Petersen, J.K., Wesseling, P., Molecular pathology of tumors of the central nervous system. Ann Oncol 30:8 (2019), 1265–1278.
de Souza, C.F., Sabedot, T.S., Malta, T.M., et al. A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence. Cell Rep 23:2 (2018), 637–651.
Reis, G.F., Pekmezci, M., Hansen, H.M., et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol 74:5 (2015), 442–452.
Brat, D.J., Aldape, K., Colman, H., et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:3 (2020), 603–608.
Barthel, F.P., Wesseling, P., Verhaak, R.G.W., Reconstructing the molecular life history of gliomas. Acta Neuropathol 135:5 (2018), 649–670.
Wang, Q., Hu, B., Hu, X., et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32:1 (2017), 42–56.e6.
Phillips, H.S., Kharbanda, S., Chen, R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:3 (2006), 157–173.
Verhaak, R.G.W., Hoadley, K.A., Purdom, E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:1 (2010), 98–110.
Ceccarelli, M., Barthel, F.P., Malta, T.M., et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:3 (2016), 550–563.
Brennan, C.W., Verhaak, R.G.W., McKenna, A., et al. The somatic genomic landscape of glioblastoma. Cell, 155(2), 2013, 462.
Cooper, L.A.D., Gutman, D.A., Chisolm, C., et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 180:5 (2012), 2108–2119.
Killela, P.J., Reitman, Z.J., Jiao, Y., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:15 (2013), 6021–6026.
Diplas, B.H., He, X., Brosnan-cashman, J.A., et al. The genomic landscape of TERT promoter. Nat Commun 9:1 (2018), 1–11.
Klughammer, J., Kiesel, B., Roetzer, T., et al. The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nat Med 24:10 (2018), 1611–1624.
Malta, T.M., de Souza, C.F., Sabedot, T.S., et al. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol 20:5 (2018), 608–620.
Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:10 (2005), 987–996.
Prager, B.C., Xie, Q., Bao, S., Rich, J.N., Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24:1 (2019), 41–53.
Schiffer, D., Annovazzi, L., Casalone, C., et al. Glioblastoma: microenvironment and niche concept. Cancers (Basel), 11, 2019, 5.
Neftel, C., Laffy, J., Filbin, M.G., et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178:4 (2019), 835–849.e21.
Dirkse, A., Golebiewska, A., Buder, T., et al. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun, 10(1), 2019, 1787.
Sampson, J.H., Gunn, M.D., Fecci, P.E., Ashley, D.M., Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20:1 (2020), 12–25.
Pires-Afonso, Y., Niclou, S.P., Michelucci, A., Revealing and harnessing tumour-associated microglia/macrophage heterogeneity in glioblastoma. Int J Mol Sci, 21(3), 2020, 689.
Hambardzumyan, D., Gutmann, D.H., Kettenmann, H., The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 19:1 (2016), 20–27.
Chen, P., Zhao, D., Li, J., et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell 35:6 (2019), 868–884.e6.
Castro, B.A., Flanigan, P., Jahangiri, A., et al. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene 36:26 (2017), 3749–3759.
Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression HHS Public Access Author manuscript. Nat Med 19:10 (2013), 1264–1272.
Butowski, N., Colman, H., De Groot, J.F., et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 18:4 (2016), 557–564.
Quail, D.F., Joyce, J.A., Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin Cancer Res 23:4 (2017), 876–884.
Kaffes, I., Szulzewsky, F., Chen, Z., et al. Human mesenchymal glioblastomas are characterized by an increased immune cell presence compared to proneural and classical tumors. Oncoimmunology, 8(11), 2019, e1655360.
Quail, D.F., Bowman, R.L., Akkari, L., et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science, 352(6288), 2016, aad3018.
Zou, J.P., Morford, L.A., Chougnet, C., et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162:8 (1999), 4882–4892.
Abedalthagafi, M., Barakeh, D., Foshay, K.M., Immunogenetics of glioblastoma: the future of personalized patient management. NPJ Precis Oncol, 2, 2018, 27.
Amankulor, N.M., Kim, Y., Arora, S., et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev 31:8 (2017), 774–786.
Kohanbash, G., Carrera, D.A., Shrivastav, S., et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest 127:4 (2017), 1425–1437.
Coffelt, S.B., Wellenstein, M.D., De Visser, K.E., Neutrophils in cancer: neutral no more. Nat Rev Cancer 16:7 (2016), 431–446.
Heiland, D.H., Haaker, G., Delev, D., et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget 8:26 (2017), 42214–42225.
Berghoff, A.S., Kiesel, B., Widhalm, G., et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol 19:11 (2017), 1460–1468.
Oh, T., Ivan, M.E., Sun, M.Z., et al. PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy 6:6 (2014), 737–753.
Newman, A.M., Liu, C.L., Green, M.R., et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:5 (2015), 453–457.
Fox, E., Oliver, T., Rowe, M., et al. Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer. Front Oncol, 8, 2018, 370.
Patel, A.P., Tirosh, I., Trombetta, J.J., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:6190 (2014), 1396–1401.
Wen, P.Y., Weller, M., Lee, E.Q., et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22:8 (2020), 1073–1113.
Ohgaki, H., Kleihues, P., Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:5 (2007), 1445–1453.
Ohgaki, H., Kleihues, P., The definition of primary and secondary glioblastoma. Clin Cancer Res 19:4 (2013), 764–772.
Nathanson, D.A., Gini, B., Mottahedeh, J., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:6166 (2014), 72–76.
Shin, Y.J., Sa, J.K., Lee, Y., et al. PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. J Exp Med 216:5 (2019), 1120–1134.
Mecca, C., Giambanco, I., Donato, R., Arcuri, C., Targeting mTOR in glioblastoma: rationale and preclinical/clinical evidence. Dis Markers, 2018, 2018, 9230479.
Reardon, D.A., Groves, M.D., Wen, P.Y., et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 19:4 (2013), 900–908.
Reardon, D.A., Nabors, L.B., Mason, W.P., et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol 17:3 (2015), 430–439.
Chakravarti, A., Wang, M., Robins, H.I., et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 85:5 (2013), 1206–1211.
Verhaak, R.G.W., Bafna, V., Mischel, P.S., Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. Nat Rev Cancer 19:5 (2019), 283–288.
Weller, M., Butowski, N., Tran, D.D., et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:10 (2017), 1373–1385.
Turner, K.M., Deshpande, V., Beyter, D., et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature 543:7643 (2017), 122–125.
Decarvalho, A.C., Kim, H., Poisson, L.M., et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet 50:5 (2018), 708–717.
Chinnaiyan, P., Won, M., Wen, P.Y., et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. Neuro Oncol 20:5 (2018), 666–673.
Ma, D.J., Galanis, E., Anderson, S.K., et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 17:9 (2015), 1261–1269.
Babak, S., Mason, W.P., MTOR inhibition in glioblastoma: requiem for a dream?. Neuro Oncol 20:5 (2018), 584–585.
Wick, W., Gorlia, T., Bady, P., et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res 22:19 (2016), 4797–4806.
Choi, B.D., Maus, M.V., June, C.H., Sampson, J.H., Immunotherapy for glioblastoma: adoptive T-cell strategies. Clin Cancer Res 25:7 (2019), 2042–2048.
Maude, S.L., Frey, N., Shaw, P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:16 (2014), 1507–1517.
Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:6 (2015), 540–549.
Sampson, J.H., Choi, B.D., Sanchez-Perez, L., et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20:4 (2014), 972–984.
O'Rourke, D.M., Nasrallah, M.P., Desai, A., et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med, 9, 2017, eaaa0984.
Akhavan, D., Alizadeh, D., Wang, D., et al. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev 290:1 (2019), 60–84.
Prinzing, B.L., Gottschalk, S.M., Krenciute, G., CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?. Expert Rev Anticancer Ther 18:5 (2018), 451–461.
Brown, C.E., Badie, B., Barish, M.E., et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res 21:18 (2015), 4062–4072.
Brown, C.E., Alizadeh, D., Starr, R., et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:26 (2016), 2561–2569.
Fecci, P.E., Sampson, J.H., The current state of immunotherapy for gliomas: an eye toward the future. J Neurosurg 131:3 (2019), 657–666.
Lang, F.F., Conrad, C., Gomez-Manzano, C., et al. Phase I study of DNX-2401 (delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36:14 (2018), 1419–1427.
Van Den Bossche, W.B.L., Kleijn, A., Teunissen, C.E., et al. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro Oncol 20:11 (2018), 1494–1504.
Desjardins, A., Gromeier, M., Herndon, J.E., et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:2 (2018), 150–161.
Liu, F., Huang, J., Xiong, Y., et al. Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma. Aging (Albany NY) 11:15 (2019), 5463–5482.
Li, X.-Y., Das, I., Lepletier, A., et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest 128:6 (2018), 2613–2625.
Kurokawa, C., Iankov, I.D., Anderson, S.K., et al. Constitutive interferon pathway activation in tumors as an efficacy determinant following oncolytic virotherapy. J Natl Cancer Inst 110:10 (2018), 1123–1132.
Cloughesy, T.F., Landolfi, J., Hogan, D.J., et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med, 8(341), 2016, 341ra75.
Cloughesy, T., Petrecca, K., Walbert, T., et al. LTBK-08. TOCA 511 & TOCA FC versus standard of care in patients with recurrent high grade glioma. Neuro Oncol, 21, 2019, vi284.
Bersanelli, M., Buti, S., From targeting the tumor to targeting the immune system: transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol 8:1 (2017), 37–53.
Berghoff, A.S., Kiesel, B., Widhalm, G., et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17:8 (2015), 1064–1075.
Nduom, E.K., Wei, J., Yaghi, N.K., et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18:2 (2016), 195–205.
Omuro, A., Vlahovic, G., Lim, M., et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 20:5 (2018), 674–686.
Bristol-Myers Squibb Provides Update on Phase 3 Opdivo (nivolumab) CheckMate -548 Trial in Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme. BMS Newsroom. Available at https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-provides-update-phase-3-opdivo-nivolumab- Accessed September 5, 2019.
Cloughesy, T.F., Mochizuki, A.Y., Orpilla, J.R., et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25:3 (2019), 477–486.
Schalper, K.A., Rodriguez-Ruiz, M.E., Diez-Valle, R., et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25:3 (2019), 470–476.
Russell, L., Peng, K.W., Russell, S.J., Diaz, R.M., Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs 33:5 (2019), 485–501.
Killock, D., BRAF+MEKi and ICI triplets show promise in melanoma. Nat Rev Clin Oncol, 16(9), 2019, 525.
Song, T.L., Nairismägi, M.L., Laurensia, Y., et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 132:11 (2018), 1146–1158.
Le Rhun, E., Preusser, M., Roth, P., et al. Molecular targeted therapy of glioblastoma. Cancer Treat Rev, 80, 2019, 101896.
Daniel, P., Sabri, S., Chaddad, A., et al. Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol, 9, 2019, 41.
Bouffet, E., Larouche, V., Campbell, B.B., et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:19 (2016), 2206–2211.
Johanns, T.M., Bowman-Kirigin, J.A., Liu, C., Dunn, G.P., Targeting neoantigens in glioblastoma: an overview of cancer immunogenomics and translational implications. Neurosurgery 64:CN_suppl_1 (2017), 165–176.
Touat, M., Li, Y.Y., Boynton, A.N., et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:7804 (2020), 517–523.
Fabian, D., Eibl, M.D.P.G.P., Alnahhas, I., et al. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review. Cancers (Basel), 11(2), 2019, 174.
Kirson, E.D., Gurvich, Z., Schneiderman, R., et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 64:9 (2004), 3288–3295.
Kirson, E.D., Dbaly, V., Tovarys, F., et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 104:24 (2007), 10152–10157.
Berger, T.R., Wong, E.T., Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies. Chinese Clin Oncol, 9, 2020, 204.
Stupp, R., Taillibert, S., Kanner, A., et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. JAMA 318:23 (2017), 2306–2316.
Connock, M., Auguste, P., Dussart, C., et al. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. J Neurooncol 143:3 (2019), 605–611.
Herrlinger, U., Tzaridis, T., Mack, F., et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOAe–09): a randomised, open-label, phase 3 trial. Lancet 393:10172 (2019), 678–688.
Lazaridis, L., Schäfer, N., Teuber-Hanselmann, S., et al. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. J Cancer Res Clin Oncol 146:3 (2020), e787–e792.
Gambella, A., Senetta, R., Collemi, G., et al. NTRK fusions in central nervous system tumors: a rare, but worthy target. Int J Mol Sci, 21(3), 2020, 753.
Xu, T., Wang, H., Huang, X., et al. Gene fusion in malignant glioma: an emerging target for next-generation personalized treatment. Transl Oncol 11:3 (2018), 609–618.
Solomon, J.P., Benayed, R., Hechtman, J.F., et al. Identifying patients with NTRK fusion cancer. Ann Oncol 30:Suppl_8 (2019), viii16–viii22.
Kim, J., Lee, Y., Cho, H.-J., et al. NTRK1 Fusion in glioblastoma multiforme. PLoS One, 9(3), 2014, e91940.
Gambella, A., Senetta, R., Collemi, G., et al. NTRK fusions in central nervous system tumors: a rare, but worthy target. Int J Mol Sci, 21(3), 2020, 753.
Behling, F., Schittenhelm, J., Oncogenic BRAF alterations and their role in brain tumors. Cancers (Basel), 11(6), 2019, 794.
Schreck, K.C., Grossman, S.A., Pratilas, C.A., BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors. Cancers (Basel), 11(9), 2019, 1262.
Kaley, T., Touat, M., Subbiah, V., et al. BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:35 (2018), 3477–3484.
Ceccon, G., Werner, J.M., Dunkl, V., et al. Dabrafenib treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation. Int J Mol Sci, 19(4), 2018, 1090.
TCGA. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 55:7216 (2008), 1061–1068.
Brennan, C.W., Verhaak, R.G.W., McKenna, A., et al. The somatic genomic landscape of glioblastoma. Cell 155:2 (2013), 462–477.
Gusev, Y., Bhuvaneshwar, K., Song, L., et al. Data descriptor: the REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci Data 5 (2018), 1–9.
Puchalski, R.B., Shah, N., Miller, J., et al. An anatomic transcriptional atlas of human glioblastoma. Science 360:6389 (2018), 660–663.
Barthel, F.P., Johnson, K.C., Varn, F.S., et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576:7785 (2019), 112–120.
